RPRathi Prasad

Rathi Prasad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rathi Prasad has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study

    by Sebastian Castro, Kyla Ng Yin, Francesco D’aNiello, Emma C Alexander, Emily Connolly, Claire Hughes, Lee Martin, Rathi Prasad, Helen L Storr, Ruben H Willemsen, et al.

    STUDY QUESTION: Are recombinant FSH (rFSH) and hCG effective therapies for promoting testicular growth and spermatogenesis in male adolescents and young adults with gonadotropin deficiency? SUMMARY ANSWER: Combined gonadotropin therapy is effective in inducing puberty and promoting spermatogenesis in male adolescents and young adults with gonadotropin deficiency and has the potential to improve adult outcomes relating to both fertility and quality of life. WHAT IS KNOWN ALREADY: Deficiency of pituitary gonadotropins (LH and FSH) due to hypogonadotropic hypogonadism (HH) can result in poor testicular development, low testicular volumes, micropenis and cryptorchidism. Inadequate hormonal replacement can lead to long-term issues, including subfertility or infertility, and reduced quality of life. Exogenous testosterone for pubertal induction can elevate serum testosterone concentrations and induce virilization, but it does not promote testicular development nor induce spermatogenesis. Fertility and testes growth remain primary concerns for patients seeking treatment. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective observational review of male adolescents and young adults with gonadotropin deficiency and seeking puberty replacement therapy at two large tertiary centre hospitals in London, UK, from 2010 to 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 35 males, with diagnosis of congenital hypogonadotropic hypogonadism (CHH: n = 23; further subdivided into those with partial [pHH: n = 8] and those with complete gonadotropin deficiency [cHH: n = 15]), acquired HH (AHH: n = 4) or Kallmann syndrome (KS: n = 8), received combined gonadotropin therapy. We assessed testicular growth and semen quality post-treatment. MAIN RESULTS AND THE ROLE OF CHANCE: The majority of patients were referred for pubertal delay, alone or in combination with cryptorchidism, micropenis or microorchidism. Out of 35 patients, 22 (63%) had previously received testosterone, and the median age at gonadotropin treatment initiation was 15.8 years (range: 11.8–22.7). Semen analysis was obtained in 18 out of 19 patients who had received gonadotropin therapy for a median treatment duration of 21.1 months (range: 4.5–66.9) for rFSH and 19.5 months (range: 8.3–61.1) for hCG. The median sperm count on semen analysis was 8.9 × 106/ml (range: 0.0–54.9). Significant increases were noted in testicular volume (median change after therapy: 10.5 ml [95% CI 9.5–13.6], P < 0.0001), testosterone (median increase: 25.7 nmol/l [95% CI 19.8–31.5], P < 0.0001) and inhibin B levels (67.7 pg/ml [95% CI 18.4–86.7], P = 0.0008). LIMITATIONS, REASONS FOR CAUTION: The relatively low representation of patients with acquired HH in our study emphasizes the need to extrapolate the findings with caution in this specific subgroup of adolescent males with HH. The study is also an observational one, therefore meaning that some outcomes (such as change in inhibin B concentration) were not collected routinely and not reported for all patients. The observational nature of the study design also accounts for the differences in doses and duration observed in gonadotropin therapy. WIDER IMPLICATIONS OF THE FINDINGS: The treatment of adult male infertility is particularly difficult in severe forms of gonadotropin deficiency, where there has been no testicular stimulation during mini-puberty or puberty. Appropriate hormonal replacement in puberty with combined gonadotropins can induce testicular maturation and spermatogenesis, but data are limited and at present, there is no international consensus on best practice regimens in adolescent and young adult males. Our treatment protocol induced testicular growth and caused increases in serum testosterone and Sertoli cell biomarkers, and spermatogenesis in 15/18 of patients who had completed semen analysis. This indicates the potential to substantially improve the reproductive, physical, and psychological health of patients who have a significant and unmet need for adequate hormonal replacement during puberty. The study described here included patients with diverse forms of HH (congenital, acquired, complete, and partial HH), thereby providing encouraging results across a variety of subjects with impaired puberty facing increased odds of fertility problems in adulthood. Additionally, we observed similar sperm counts between those who received exogenous testosterone treatment prior to gonadotropin therapy and those who began directly on gonadotropins for pubertal induction. This last finding is aligned with previous data and may help to reassure paediatric endocrinologists with limited access to rFSH or hCG that the use of exogenous testosterone to induce androgen-dependent changes in patients seeking treatment for pubertal delay is unlikely to compromise spermatogenic potential, should gonadotropins become available at a later stage. STUDY FUNDING/COMPETING INTEREST(S): S.C. was funded by an ESPE Early Career Scientific Development Grant. S.R.H. was funded by the Wellcome Trust (222049/Z/20/Z) and Barts Charity [MGU0552]. K.N.Y. was employed under the NIHR Specialist Foundation Programme. F.d.A. was funded by the student traineeship, University of Rome ‘Tor Vergata’, an Erasmus Grant and an ESPE Early Career Scientific Development Grant. E.C.A. was funded by an NIHR Academic Clinical Fellowship (ACF-2021-19-002). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS, or the UK Department of Health and Social Care. G.B. received an ESPE Mid-Career Research Fellowship to enable the development of the clinical treatment schedule. The authors have no conflicting interests. TRIAL REGISTRATION NUMBER: N/A.


  • Open Access

    Ichthyosis linked to sphingosine 1-phosphate lyase insufficiency is due to aberrant sphingolipid and calcium regulation

    by Christopher J. Smith, Jack L. Williams, Charlotte Hall, Josefina Casas, Matthew P. Caley, Edel A. O'TOole, Rathi Prasad, Louise A. Metherell


  • Open Access

    Elevated sphingosine-1-phosphate lyase leads to increased metabolism and reduced survival in adrenocortical carcinoma

    by Jack L Williams, Chris Smith, Charlotte Hall, Zakaa Khaled, Avinaash Maharaj, Ruth Kwong, James Pittaway, Josefina Casas, Laila Parvanta, Tarek Ezzat Abdel-Aziz, et al.

    Adrenocortical carcinomas (ACCs) are invasive tumours arising in the adrenal cortex, and steroidogenic tumours are associated with worse prognostic outcomes. Loss-of-function mutations in sphingosine-1-phosphate lyase (SGPL1) cause primary adrenal insufficiency and as a key degradative enzyme in the sphingolipid pathway, SGPL1 also influences the balance of pro-proliferative and pro-apoptotic sphingolipids. We, therefore, hypothesized increased SGPL1 may be linked to increased disease severity in ACC. Analyse SGPL1 expression impact on patient survival and adrenal cancer cell phenotype. We analysed two ACC cohorts with survival and corresponding transcriptomic data, focusing on SGPL1 and sphingolipid pathway genes. In vitro, we generated SGPL1-knockout and overexpressing H295R adrenocortical cells to investigate the role of SGPL1 in cell signalling in ACCs. We found increased expression of several sphingolipid pathway receptors and enzymes, most notably SGPL1 correlated with reduced patient survival in both cohorts. Overexpression of SGPL1 in the H295R cell line increased proliferation and migration while reducing apoptosis, while SGPL1 knockout had the opposite effect. RNA-seq revealed a global increase in the expression of genes in the electron transport chain in overexpressing cells, correlating with increased aerobic respiration and glycolysis. Furthermore, the opposite phenotype was seen in cells lacking SGPL1. We subsequently found the increased proliferation is linked to metabolic substrate availability and increased capacity to use different fuel sources, but particularly glucose, in overexpressing cells. We, therefore, propose that SGPL1-overexpressing ACC tumours reduce patient survival by increasing fuel usage for anabolism and energy production to facilitate growth and invasion.


  • The lack of genotype: phenotype correlations in rare causes of primary adrenal insufficiency highlights the need for genetic testing

    by Saptarshi Maitra, Christopher Smith, Charlotte Hall, Jordan Read, Avinaash V Maharaj, Marroquin Ramirez Lucia Mariela, Younus Qamar, Rathi Prasad, Li F Chan, Louise A Metherell

    Background: Primary adrenal insufficiency (PAI) can be associated with significant morbidity in children of all ages, the most common cause being Congenital Adrenal Hyperplasia (CAH). Several other rare inherited causes of PAI have been identified over the years which lack diagnostic phenotypic or biochemical signs, leaving genetic testing as the only approach to make a definitive diagnosis. Our cohort involves >440 patients who presented with features of PAI – hypoglycaemia, hyperpigmentation and hypocortisolaemia without diagnostic characteristics of CAH. Targeted and whole exome sequencing has been conducted in 377 patients to date. Aim: Genotype:phenotype characterisation for our cohort’s five most common genes causing PAI. Results: We identified the genetic cause in 322/377 patients, the most common being mutations in MC2R (n=68/322), MRAP (n=53/322), NNT (n=44/322), STAR (n=28/322) and CYP11A1 (n=23/322). The relative risk of early age of onset of symptoms with an MRAP mutation as compared to other gene mutations causing PAI within our cohort was 1.5158 (95%CI: 0.9988-2.3003, PPP<0.0001) amongst our cohort. For CYP11A1 2/4 (50%) adrenals were described as small whereas for all others only 11/102 (11%) were abnormal. No other significant association with height or levels of other steroids were found between the genotypic and phenotypic characteristics of PAI. Discussion: A limitation of this study was the small sample size for each gene defect owing to the rarity of the disease. Our results suggest MRAP mutations present the earliest with lowest cortisol, while CYP11A1 have higher cortisol and smaller adrenal size however, with overlapping ranges this cannot be used for diagnosis. For CYP11A1 the higher cortisol levels may be due to over-representation of partial loss-of-function rs6161 variant in our population. These findings also highlight the importance of genetic testing since few clear genotype:phenotype correlations are obvious at diagnosis. Gaining a genetic diagnosis allows for the monitoring of patients for the pathological sequelae which can develop with different forms of PAI.

  • ESDR181 - Sphingosine 1-phosphate lyase insufficiency induced ichthyosis is due to sphingolipid imbalance, increased differentiation, and aberrant intercellular junctions.

    by Chris Smith, Jack Williams, Charlotte Hall, Matthew Caley, Edel O'Toole, Rathi Prasad, Louise Metherell

    Sphingosine 1-phosphate lyase (SGPL1) insufficiency (SPLIS) is a syndrome which presents not only with ichthyosis but also with adrenal insuffici | POSTER

  • Open Access

    A retrospective analysis of endocrine disease in sphingosine-1-phosphate lyase insufficiency: case series and literature review

    by Avinaash Maharaj, Ruth Kwong, Jack Williams, Christopher Smith, Helen Storr, Ruth Krone, Debora Braslavsky, Maria Clemente, Nanik Ram, Indraneel Banerjee, et al.

    Sphingosine-1-phosphate lyase (SGPL1) insufficiency syndrome (SPLIS) is an autosomal recessive multi-system disorder, which mainly incorporates steroid-resistant nephrotic syndrome and primary adrenal insufficiency. Further variable endocrine manifestations are described. We aimed to comprehensively annotate the endocrinopathies associated with pathogenic SGPL1 variants and assess for genotype-phenotype correlations by retrospectively reviewing reports of endocrine disease within our patient cohort and all published cases in the wider literature up to January 2022. Glucocorticoid insufficiency in early childhood is the most common endocrine manifestation affecting 64% of the 50 patients reported with SPLIS, a third of these individuals have additional mineralocorticoid deficiency. Whilst most individuals also have nephrotic syndrome, SGPL1 variants also account for isolated adrenal insufficiency at presentation. Primary gonadal insufficiency, manifesting with microphallus and cryptorchidism, is reported in less than one third of affected boys, all with concomitant adrenal disease. Mild primary hypothyroidism affects approximately a third of patients. There is paucity of data on the impact of SGPL1 deficiency on growth, and pubertal development, limited by the early and high mortality rate (approximately 50%). There is no clear genotype-phenotype correlation overall in the syndrome, with variable disease penetrance within individual kindreds. However, with regards to endocrine phenotype the most prevalent disease variant p.R222Q (affecting 22%) is most consistently associated with isolated glucocorticoid deficiency. We conclude that SPLIS is associated with significant multiple endocrine disorders. Whilst endocrinopathy in the syndrome generally presents in infancy, late onset disease also occurs. Screening for these is therefore warranted both at diagnosis and through follow-up.


  • Open Access

    Insights From Long-term Follow-up of a Girl With Adrenal Insufficiency and Sphingosine-1-Phosphate Lyase Deficiency

    by Avinaash Maharaj, Tülay Güran, Federica Buonocore, John C Achermann, Louise Metherell, Rathi Prasad, Semra Çetinkaya

    Introduction Sphingosine-1-phosphate lyase (SGPL1) insufficiency syndrome (SPLIS) is a multisystemic disorder which, in the main, incorporates steroid-resistant nephrotic syndrome and primary adrenal insufficiency (PAI). Case Presentation We present a young girl with a novel homozygous variant in SGPL1, p.D350G, with PAI in the absence of nephrotic syndrome. In the course of 15 years of follow-up she has further developed primary hypothyroidism and while she has progressed through puberty appropriately, ovarian calcifications were noted on imaging. The p.D350G variant results in reduced protein expression of SGPL1. We demonstrate that CRISPR engineered knockout of SGPL1 in human adrenocortical (H295R) cells abrogates cortisol production. Furthermore, while wild-type SGPL1 is able to rescue cortisol production in this in vitro model of adrenal disease, this is not observed with the p.D350G mutant. Conclusion SGPL1 deficiency should be considered in the differential diagnosis of PAI with close attention paid to evolving disease on follow-up.


  • Open Access

    Genetic Analysis of Pediatric Primary Adrenal Insufficiency of Unknown Etiology: 25 Years’ Experience in the UK

    by Federica Buonocore, Avinaash Maharaj, Younus Qamar, Katrin Koehler, Jenifer P Suntharalingham, Li F Chan, Bruno Ferraz-De-Souza, Claire R Hughes, Lin Lin, Rathi Prasad, et al.

    Context Although primary adrenal insufficiency (PAI) in children and young people is often due to congenital adrenal hyperplasia (CAH) or autoimmunity, other genetic causes occur. The relative prevalence of these conditions is poorly understood. Objective We investigated genetic causes of PAI in children and young people over a 25 year period. Design, Setting and Participants Unpublished and published data were reviewed for 155 young people in the United Kingdom who underwent genetic analysis for PAI of unknown etiology in three major research centers between 1993 and 2018. We pre-excluded those with CAH, autoimmune, or metabolic causes. We obtained additional data from NR0B1 (DAX-1) clinical testing centers. Intervention and Outcome Measurements Genetic analysis involved a candidate gene approach (1993 onward) or next generation sequencing (NGS; targeted panels, exomes) (2013-2018). Results A genetic diagnosis was reached in 103/155 (66.5%) individuals. In 5 children the adrenal insufficiency resolved and no genetic cause was found. Pathogenic variants occurred in 11 genes: MC2R (adrenocorticotropin receptor; 30/155, 19.4%), NR0B1 (DAX-1; 7.7%), CYP11A1 (7.7%), AAAS (7.1%), NNT (6.5%), MRAP (4.5%), TXNRD2 (4.5%), STAR (3.9%), SAMD9 (3.2%), CDKN1C (1.3%), and NR5A1/steroidogenic factor-1 (SF-1; 0.6%). Additionally, 51 boys had NR0B1 variants identified through clinical testing. Although age at presentation, treatment, ancestral background, and birthweight can provide diagnostic clues, genetic testing was often needed to define the cause. Conclusions PAI in children and young people often has a genetic basis. Establishing the specific etiology can influence management of this lifelong condition. NGS approaches improve the diagnostic yield when many potential candidate genes are involved.


  • Open Access

    Sphingosine 1- Phosphate Lyase Insufficiency Syndrome (SPLIS); A Role in Multiple Endocrinopathies

    by Ruth Ming Wai Kwong, Avinaash Vickram Maharaj, Louise Metherell, Rathi Prasad

    Sphingosine 1-phosphate lyase insufficiency syndrome (SPLIS) was described in 2017 as a novel condition affecting sphingolipid metabolism. There is a multisystemic phenotype including nephrotic syndrome and primary adrenal insufficiency (PAI) and to a lesser extent ichthyosis, neurological disease and lymphopenia. A proportion of patients also presented with hypothyroidism and hypogonadism. To interrogate the endocrine aspect of the syndrome we reviewed clinical data within our patient cohort with SPLIS and those within the wider literature. To date there have been 45 patients identified with SPLIS with significant associated mortality (n=23/45, 51%; 4 of these in utero). There is no clear genotype-phenotype correlation. Whilst nephrotic syndrome is most prevalent (n=34/45; 76%), a significant proportion of patients (n=27/45, 60%) also presented with glucocorticoid deficiency, some with additional mineralocorticoid deficiency (n=7/27). Five further patients were noted to have adrenal calcifications though biochemistry was not undertaken. Most patients presented with PAI in the first 2 years of life (n=21/27), with the oldest presentation being 11 years of age. Adrenal calcifications are a common finding in those who had documented imaging (n=13/15, 87%). Primary gonadal failure has been reported in 8 male cases, all with concomitant PAI. Presenting features included microphallus (n=7/8) and cryptorchidism (n=8/8), indicating reduced in utero androgen exposure. All who had biochemical evaluation demonstrated raised basal LH and FSH/ exaggerated response to LHRH stimulation, a lack of testosterone response to HCG stimulation and low antimullerian hormone (AMH) levels. To date there are no reports of pubertal delay in female patients, and those of age within our cohort have normal ovarian reserve as evidenced by AMH levels (n=2). Primary hypothyroidism, with mildly raised TSH and low Free T4 is reported in 12 patients. Most did not have goiters and had concomitant PAI and nephrotic syndrome (n=11/12). SPLIS is unique amongst sphingolipid disorders in presenting with significant endocrinopathy. This may be the consequence of the particular sphingolipid signature of the disease and the pathogenic mechanisms need to be explored further. It is clear that endocrine dysfunction needs to be considered at diagnosis and surveillance undertaken to detect evolving disease which could have a significant impact on morbidity and mortality.


  • Open Access

    Sphingosine-1-phosphate lyase (SGPL1) deficiency is associated with mitochondrial dysfunction

    by A. Maharaj, J. Williams, T. Bradshaw, T. Güran, D. Braslavsky, J. Casas, L.F. Chan, L.A. Metherell, R. Prasad